Recursion Pharmaceuticals (RXRX) stock surged after the company significantly beat Street forecasts with its Q4 2025 results.
Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...
A January 2026 class action alleges that Eightfold AI scraped personal data on over one billion workers, scored job ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results